A
Amena Etherington
Researcher at University of Maryland, Baltimore County
Publications - 4
Citations - 697
Amena Etherington is an academic researcher from University of Maryland, Baltimore County. The author has contributed to research in topics: Aspirin & Clopidogrel. The author has an hindex of 4, co-authored 4 publications receiving 682 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of Dose-Related Effects of Aspirin on Platelet Function Results From the Aspirin-Induced Platelet Effect (ASPECT) Study
Paul A. Gurbel,Kevin P. Bliden,Joseph DiChiara,Justin Newcomer,Willy Weng,Nagaraj K. Neerchal,Tania Gesheff,Srivasavi K. Chaganti,Amena Etherington,Udaya S. Tantry +9 more
TL;DR: The observation of dose-dependent effects despite nearly complete inhibition of AA-induced aggregation suggests that aspirin may exert antiplatelet properties through non–cyclooxygenase-1 pathways and deserves further investigation.
Journal ArticleDOI
Response to the Letter Regarding Article, “Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study”
Paul A. Gurbel,Kevin P. Bliden,Joseph DiChiara,Tania Gesheff,Srivasavi K. Chaganti,Amena Etherington,Udaya S. Tantry,Justin Newcomer,Willy Weng,Nagaraj K. Neerchal +9 more
TL;DR: The compliance of patients in ASPECT was meticulously recorded and, as reported in the manuscript, was overall 98%. as discussed by the authors showed that only 1 compliant patient was observed in the ASPECT trial.
Journal ArticleDOI
Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
TL;DR: Clopidogrel responsiveness is higher when measured by FA as compared to MA, however, these measurements are equivalent in determining the prevalence of non-responsiveness: FA and MA are affected to the same degree in patients with non- Responsiveness.
Journal ArticleDOI
Antiplatelet therapy: current strategies and future trends.
TL;DR: An important future step will probably be the development of personalized therapy based on defining the individual patient's propensity for thrombosis through investigation of platelet-thrombin-fibrin interactions.